Skip to content
Aminoscope
← Research
GLP-1

How to get Zepbound: the three routes to a prescription

Zepbound is prescription-only. Here's who qualifies, and the three legitimate routes — your clinician, telehealth, or LillyDirect — plus why there's no legal no-prescription shortcut.

Nadia Feldman6 min read
Every legitimate route to Zepbound runs through a prescriptionin-person cliniciantelehealth visitLillyDirectprescriptionZepboundTHREE ROUTES · ALL THROUGH A PRESCRIPTION

Getting Zepbound is more straightforward than getting an off-label drug, but it still has exactly one kind of starting point: a prescription from a licensed clinician. There are three practical routes to that prescription, and they differ mostly in convenience. This piece is about access; for what you’ll actually pay once you have a prescription, see Zepbound cost.

First, who qualifies

Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with a BMI of 30 or higher (obesity), or a BMI of 27 or higher (overweight) plus at least one weight-related condition — such as high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease.[1] It is separately approved for moderate-to-severe obstructive sleep apnea in adults with obesity.[1] A legitimate prescriber will check that you meet these criteria; a service that prescribes it to anyone regardless of BMI is a red flag, not a convenience.

The three routes to a prescription

In person. Your primary-care clinician or an obesity-medicine specialist can evaluate you, confirm you qualify, and send the prescription to a pharmacy. This is the route that integrates best with the rest of your care and your existing insurance.

Telehealth. A licensed telehealth platform can do the evaluation by video or questionnaire-plus-review, confirm eligibility, and prescribe. The good ones still involve a real clinician and real follow-up; the test is whether there’s a licensed prescriber accountable for your care, not just a checkout flow.

LillyDirect. Lilly’s own platform connects patients to independent telehealth prescribers and fulfills the medication — shipping single-dose vials at the self-pay prices covered in our cost guide.[2] It’s a streamlined cash route for people without coverage; a valid prescription is still required.

Three legitimate routes, all requiring a prescription — and one category to avoid entirely.
RouteBest forPrescription required?
In-person clinicianIntegrated care + using insuranceYes
Telehealth platformConvenience with a real prescriberYes
LillyDirectCash self-pay, vials shippedYes
'Research' / no-Rx sellersNothing — avoidNo (not legitimate)
Three legitimate routes, all requiring a prescription — and one category to avoid entirely. Lilly (LillyDirect); FDA-approved indication per the Zepbound label

What a legitimate visit looks like

Whichever route you choose, a credible evaluation covers your weight history and BMI, your other medical conditions and medications, and a plan for follow-up — because Zepbound is titrated slowly from a 2.5 mg starting dose and monitored for tolerability. If a service skips the eligibility check, prescribes without any clinician review, or won’t be there for follow-up, that’s not a faster version of the same thing — it’s a worse one.

The honest bottom line

To get Zepbound: confirm you meet the BMI criteria, then choose a route to a prescription — your own clinician (best if you’re using insurance), a legitimate telehealth platform (convenient), or LillyDirect (a clean cash route with vials shipped). All three require a real prescription and a real evaluation, and that’s the feature, not the friction. Once you have it, the cost guide covers what you’ll pay, and Zepbound vs Wegovy covers whether it’s the right GLP-1 for you. Our guide to GLP-1 providers lays out the telehealth options.

Reviewed against primary sources by the Aminoscope desk

Sources

  1. [1] U.S. Food and Drug Administration. (2024). Zepbound (tirzepatide) prescribing information — indications and usage. FDA label via accessdata.fda.gov. Source
  2. [2] Eli Lilly and Company. (2026). LillyDirect — Zepbound (tirzepatide). lilly.com/lillydirect (accessed June 2026). Source
  3. [3] U.S. Food and Drug Administration. (2026). FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list. FDA news release. Source

Related tool

GLP-1 weight-loss comparison

See semaglutide, tirzepatide, retatrutide and the pipeline ranked by mean trial weight loss — every figure traced to its source.

More in GLP-1